NIH RFA · NHLBI · R61, R33
RFA-HL-26-017: Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and…
- NOFO number
- RFA-HL-26-017
- Type
- RFA
- Activity code
- R61R33
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Not Allowed
- Posted
- Nov 22, 2024
- Opens
- Jan 11, 2025
- Expires
- Dec 24, 2027
RFA-HL-26-017 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 11, 2025 | February 11, 2025 | April 21, 2025 | July 2025 | October 2025 | December 2025 |
| June 18, 2025 | June 18, 2025 | August 21, 2025 | November 2025 | January 2026 | April 2026 |
| October 21, 2025 | October 21, 2025 | December 22, 2025 | March 2026 | May 2026 | July 2026 |
| February 11, 2026 | February 11, 2026 | April 21, 2026 | July 2026 | October 2026 | December 2026 |
| June 18, 2026 | June 18, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 21, 2026 | October 21, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 11, 2027 | February 11, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 17, 2027 | June 17, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 21, 2027 | October 21, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under RFA-HL-26-017
NIH RePORTER lists 4 projects funded under RFA-HL-26-017 in FY2022–FY2026, with $2.4M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
4
Distinct projects, FY2022–FY2026
New awards
4
Type 1 (new project) award records
NIH funding
$2.4M
Award dollars under RFA-HL-26-017, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 5 | 4 | $2.4M |
Institutions with the most funding
- Rice University$638K · 1 project
- Greenstone Biosciences, Inc.$626K · 1 project
- University of Alabama at Birmingham$563K · 1 project
- University of Arizona$563K · 1 project
Funding institutes
- NHLBI$2.4M · 5
Activity codes funded
- R615 records
Most recent new awards
- Targeted control of mitochondrial biogenesis as a therapy for heart failure (opens NIH RePORTER)
Rice University · 1R61HL183015-01A1 · NHLBI · Notice Aug 28, 2026
$638KR61
- Small Molecule Drug Discovery for Cardiac Fibrosis using AI/ML and iPSC-Derived Organoids (opens NIH RePORTER)
Greenstone Biosciences, Inc. · 1R61HL179715-01A1 · NHLBI · Notice Aug 3, 2026
$626KR61
- Recombinant hemopexin for the treatment of acute and chronic lung injury (opens NIH RePORTER)
University of Alabama at Birmingham · 1R61HL179700-01A1 · NHLBI · Notice Jul 7, 2026
$520KR61
- Small molecule therapeutics for heart failure through a reduction in the activity of tristetraprolin and improving cardiac metabolism. (opens NIH RePORTER)
University of Arizona · 1R61HL179722-01A1 · NHLBI · Notice Jul 6, 2026
$563KR61
What its predecessor RFA-HL-23-011 funded
RFA-HL-26-017 reissues RFA-HL-23-011. Its funding history is the best guide to who wins under this program: 26 projects and $21.5M in FY2022–FY2026.
Projects funded
26
Distinct projects, FY2022–FY2026
New awards
17
Type 1 (new project) award records
NIH funding
$21.5M
Award dollars under RFA-HL-23-011, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 5 | 5 | $2.8M |
| FY2024 | 9 | 5 | $4.8M |
| FY2025 | 15 | 7 | $7.7M |
| FY2026 | 12 | 0 | $6.2M |
Institutions with the most funding
- Cleveland Clinic Lerner Com-Cwru$3.3M · 4 projects
- University of California, San Francisco$2.2M · 3 projects
- University of Kansas Medical Center$1.6M · 2 projects
- Emory University$1.6M · 2 projects
- Texas Heart Institute$1.6M · 2 projects
- University of South Florida$1.5M · 2 projects
- University of Maryland Baltimore$1.4M · 2 projects
- University of Connecticut Sch of Med/Dnt$1.2M · 1 project
Funding institutes
- NHLBI$21.5M · 41
Activity codes funded
- R6130 records
- R3311 records
Most recent new awards
- Development of Novel RhoA Nitration Inhibitory Peptides for the Treatment of Acute Lung Injury (opens NIH RePORTER)
Florida International University · 1R61HL171783-01A1 · NHLBI · Notice Aug 26, 2025
$516KR61
- AAV therapies for TNNT2-associated cardiac disorders (opens NIH RePORTER)
University of Connecticut Sch of Med/Dnt · 1R61HL181756-01 · NHLBI · Notice Aug 19, 2025
$611KR61
- Concurrent targeting of inflammation and the inhibition of the fibrinolytic system to increase the efficacy of empyema treatment (opens NIH RePORTER)
University of Texas Hlth Ctr at Tyler · 1R61HL175690-01A1 · NHLBI · Notice Jul 9, 2025
$500KR61
- Cobinamide as a disease-modifying treatment for Marfan Syndrome: optimizaation of absorption (opens NIH RePORTER)
University of California, San Diego · 1R61HL175687-01A1 · NHLBI · Notice Jun 14, 2025
$406KR61
- Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis (opens NIH RePORTER)
Henry Ford Health + Michigan State University Health Sciences · 1R61HL177451-01 · NHLBI · Notice Mar 28, 2025
$542KR61
- Liposomal azithromycin to treat cardiac inflammation (opens NIH RePORTER)
University of Kentucky · 1R61HL177474-01 · NHLBI · Notice Mar 18, 2025
$542KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under RFA-HL-26-017. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- NIAID · National Institute of Allergy and Infectious Diseases
Related notices
Apr 28, 2026 · NOT-AI-26-002
Notice of NIAID Participation in RFA-HL-26-017, Catalyze: Product Definition for Small Molecules, Biologics and Combination Products-Target Identification and Validation, and Preliminary Product/Lead Series Identification R61/R33).
Jan 28, 2026 · NOT-OD-26-029
NIH Removing AIDS Application Due Dates from NOFOs.
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets must not exceed direct costs of 400,000 per year during the R61 phase and also must not exceed direct costs of 400,000 per year during the R33 phase. The total budget Federal award and non-Federal matching contributions) should reflect the actual needs of the overall proposed project. Annual project budgets should reflect the actual costs anticipated in each year.Cost Matching…
- Project period
- The maximum project period of the combined R61 and R33 phases is 3 years, with up to 2 years for the R61 phase and up to 2 years for the R33 phase. The R61 and the R33 cannot be awarded in the same fiscal year. The scope of the proposed project should determine the requested project award period. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications…
- Funds available and number of awards
- NHLBI intends to commit total costs of up to 4,466,000 in FY 2026, 4,466,000 in FY 2027, and 4,466,000 in FY 2028. NHLBI expects to fund up to 8 new awards in FY 2026, 8 new awards in FY 2027, and 8 new awards in FY 2028, for a total of up to 24 new awards for projects submitted to this NOFO and three companion funding opportunity announcements RFA-HL-26-018, RFA-HL-26-019, RFA-HL-26-020).The…
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-HL-23-011.
- Companion NOFOs: RFA-HL-26-016, RFA-HL-26-018, RFA-HL-26-019, RFA-HL-26-020.
Other open NOFOs for R61, R33
- RFA-HL-26-016Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-018Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-019Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-020Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- PAR-27-011Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)NHLBI · next due Feb 1, 2027
- PAR-25-025NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)NHLBI
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.